RRML - Innate Immune Mechanisms in Myocardial Infarction - An Update
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2016): 0.325

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- November 2017 -
 
Retraction of article: Risk facto... 25
Romanian Review of Laboratory Med... 13
Beta-lactam and quinolone resista... 12
The frequency of shiga-like toxin... 10
Innate Immune Mechanisms in Myoca... 7
Epidemiological data and antifung... 7
Eulogy for Aurel BIZO... 7
Effects of low-molecular weight a... 6
Association of Human Leukocyte An... 6
Co-expression of the CBFβ-MYH11 ... 4

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Ahead of print DOI:10.1515/rrlm-2017-0031
XML
TXT

Review

Innate Immune Mechanisms in Myocardial Infarction - An Update

Razvan Gheorghita Mares, Goran Marinkovic, Ovidiu Simion Cotoi, Alexandru Schiopu

Correspondence should be addressed to: Razvan Gheorghita Mares

Abstract

Acute myocardial infarction (AMI) is a disease associated with high morbidity and mortality. Currently there are no available treatments specifically targeting the post-ischemic myocardial processes that lead to heart failure and recurrent coronary events. The innate immune system plays a central role in the two consecutive phases that follow an acute ischemic event: the inflammatory phase and the reparatory phase. The inflamatory phase involves a massive infiltration of neutrophils and inflammatory Ly6Chi monocytes into the injured myocardium. The reparatory phase is orchestrated by reparatory Ly6Clo macrophages that clear necrotic and apoptotic cells through efferocytosis, secrete anti-inflammatory mediators and stimulate fibrosis and repair. Important recent studies provided proof that Ly6Chi monocytes that enter the myocardium in the inflammatory phase upregulate the orphan nuclear receptor Nr4a1 and switch phenotype to Ly6CloNr4a1hi reparatory macrophages. Additionally, neutrophils have been shown to promote cardiac recovery by upregulating expression of the efferocytosis receptor MerTK on reparatory macrophages. A finely tuned balance between the inflammatory and the reparatory phases is thus essential for limiting myocardial damage and promoting efficient recovery. Treatment strategies targeting only the inflammatory phase have so far failed to improve prognosis in AMI patients. A detailed understanding of the interplay between the two phases of the innate immune response is paramount for designing efficient therapies able to improve post-AMI prognosis. In the current review, we summarize the state-of-the-art of the field and discuss previous therapeutic attempts and currently ongoing clinical trials targeting innate immune mechanisms in AMI patients.

Keywords: myocardial infarction, innate immune system, monocytes/macrophages, neutrophils, myocardial repair

Received: 15.6.2017
Accepted: 28.8.2017
Published: 15.9.2017

 
  PDF Download full text PDF
(381 KB)